BioLife Solutions Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioLife Solutions, Inc. - BLFS

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of BioLife Solutions, Inc. (NasdaqCM: BLFS) to Repligen Corporation (NasdaqGS: RGEN). Under the terms of the proposed transaction, shareholders of BioLife will receive $11.25 in cash and 0.1442 shares of Repligen common stock for each share of BioLife that they own. KSF is seeking to determine whe.

Business Wire • Jul 24, 2026

Repligen Corporation (RGEN) M&A Call Transcript

Repligen Corporation (RGEN) M&A Call Transcript

Seeking Alpha • Jul 23, 2026

BioLife Solutions to be acquired by Repligen in $1.5B cell therapy deal

BioLife Solutions, a Bothell, Wash.-based company developing tools for cell and gene therapy, is being acquired for $1.5 billion by the life sciences corporation Repligen.

GeekWire • Jul 23, 2026

Repligen to Expand Cell Therapy Capabilities With BioLife Buyout

RGEN's $1.5 billion BioLife acquisition aims to expand its cell therapy capabilities, adding biopreservation products and expected revenue and EPS benefits.

Zacks Investment Research • Jul 23, 2026

Repligen to buy cell therapy maker BioLife in $1.5 billion deal

Repligen Corp said on ​Wednesday it would buy ‌BioLife Solutions in a cash-and-stock deal valued at about $1.5 ​billion, to expand the drugmaking ​equipment provider's presence in ⁠the fast-growing cell ​therapy market.

Reuters • Jul 22, 2026

Repligen Strengthens Cell Therapy Portfolio With BioLife Acquisition

Life sciences company Repligen Corporation (NASDAQ:RGEN) on Wednesday agreed to acquire cell processing developer BioLife Solutions Inc. (NASDAQ:BLFS) for an enterprise value of approximately $1.5 billion.

Benzinga • Jul 22, 2026

Repligen to Buy BioLife Solutions for $1.5 Billion, Expanding Cell Therapy Reach

Repligen NASDAQ: RGEN said it has signed a definitive agreement to acquire BioLife Solutions in a transaction valued at approximately $1.5 billion, adding a cell therapy-focused platform that management said will expand Repligen's exposure to one of the faster-growing areas of bioprocessing.

MarketBeat • Jul 22, 2026

Repligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities with Market Leading Biopreservation Media

Fast-tracks Repligen's leadership and customer solution offering in high-growth cell therapy market by adding BioLife's differentiated, high-margin recurring revenue business

GlobeNewsWire • Jul 22, 2026

Repligen to Report Second Quarter 2026 Financial Results

Webcast and Conference Call to Be Held Tuesday, July 28, 2026, at 8:00 a.m. ET Webcast and Conference Call to Be Held Tuesday, July 28, 2026, at 8:00 a.m. ET

GlobeNewsWire • Jul 15, 2026

Repligen (RGEN) Down 3.2% Since Last Earnings Report: Can It Rebound?

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Jun 4, 2026